多巴胺激动剂对心脏代谢风险因素的影响:系统性审查和元分析
Yizhuo Xue1, Mohammad Hassan Sohouli2, Nathalia Sernizon Guimarães3
1Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, Jiangsu, China.
Expert opinion on pharmacotherapy
|June 24, 2025
概括
多巴胺激动剂 (DA) 显著改善心脏代谢因素,如血糖,胰岛素,HbA1c和血压. 勃罗莫克里因对葡萄糖代谢标志物表现出显著的影响,表明DA.
科学领域:
- 内分泌学和新陈代谢学
- 心血管研究研究心血管研究
背景情况:
- 心脏代谢性疾病对全球健康构成重大挑战.
- 多巴胺激动剂 (DA) 已证明对心脏代谢风险因素有多种影响,需要进一步调查.
研究的目的:
- 系统地评估多巴胺激动剂 (DA) 对关键心脏代谢参数的影响.
- 综合随机对照试验的证据,以澄清DA在管理心脏代谢健康方面的疗效.
主要方法:
- 在五个主要数据库中进行了全面的文献搜索.
- 包括随机对照试验 (RCT),调查DA对心脏代谢因素的影响.
- 综合加权平均差异 (WMD) 和95%置信区间 (CI) 的元分析使用随机效应模型进行.
主要成果:
- DA干预导致禁食血糖 (FBS),胰岛素,HOMA-IR和HbA1c显著降低.
- 在DA治疗后,缩血压 (SBP) 和腹缩血压 (DBP) 也显著降低.
- 亚组分析表明,与其他DA相比,烯对葡萄糖代谢标志物表现出更明显的作用.
结论:
- 多巴胺激动剂 (DA) 对几种心脏代谢风险因素具有有益影响.
- 这些发现表明,DA可以作为一种有价值的辅助疗法,与生活方式修改一起,用于改善心脏代谢健康.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Coronary Artery Disease I: Introduction
69
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
69
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
644
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
644
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Heart Failure Drugs: β-Blockers
445
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
445


